Ramosetron hydrochloride market

Ramosetron hydrochloride, an anti-emetic drug, is prescribed for the treatment of diarrhoea-predominant irritable bowel syndrome in adults. Ramosetron hydrochloride is also prescribed for the treatment and management of postoperative nausea and/or vomiting and also associated with carcinostatic drugs including cisplatin.

Ramosetron Hydrochloride Market Driver

Rising research activities for ramosetron hydrochloride is estimated to propel the growth of ramosetron hydrochloride in the global market over projected year. For instance, according to Gastroenterology February 2016, study has shown that ramosetron is expected to reduce symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Ramosetron have shown to improve stool consistency in women. This rising research for use of ramosetron can drive the growth of global ramosetron hydrochloride market.

Ramosetron Hydrochloride Market Restraint

Adverse effects associated with the drugs such as for instance, Current Index of Medical Specialties (CIMS) 2018 states, prolog use of ramosetron hydrochloride is associated with headache, diarrhoea, constipation, allergic reactions, and severe hepatic failures which can be fatal, and can restrain the growth of ramosetron hydrochloride in the global market over forecasted year.

Ramosetron Hydrochloride Market – Regional Analysis

Based on region, the global ramosetron hydrochloride market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America region is anticipated to dominant in the growth of global ramosetron hydrochloride market attributed to prevalence of irritable bowel syndrome in U.S. For instance, Centers for Disease Control and Prevention 2015 statistics estimated 1.3% of U.S. adults (3 million) being diagnosed with irritable bowel syndrome.

Asia Pacific region is estimated to perceive noteworthy growth in the global Ramosetron Hydrochloride market owing to rising approvals for licensing of drug by regulatory bodies. For instance, in April 2015, Ministry of Health, Labour and Welfare, Japan, and Pharmaceuticals and Medical Devices Agency (PMDA) concluded that ramosetron hydrochloride, manufactured by Astellas Pharma Inc. is effective in patients with diarrhea-predominant irritable bowel syndrome and the drug was approved for marketing.

Ramosetron Hydrochloride Market – Competitive Analysis

The key players of ramosetron hydrochloride market include, Astellas Pharma Inc., Abbott Laboratories, AdvaCare Pharma, Tioga Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Pharmos Corporation, Shandong Chenlong Pharmaceutical Co. Ltd, and Alomone Labs.

Ramosetron Hydrochloride Market – Taxonomy

By Indication

• Motion Sickness
• Irritable Bowel Syndrome
• Cancer Chemotherapy associated Nausea and Vomiting
• Diarrhoea

By Application

• Hospitals
• Clinics
• Home Care

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa